WO2021165995A1 - Nouveaux sels et/ou co-cristaux de ténofovir alafénamide - Google Patents

Nouveaux sels et/ou co-cristaux de ténofovir alafénamide Download PDF

Info

Publication number
WO2021165995A1
WO2021165995A1 PCT/IN2021/050164 IN2021050164W WO2021165995A1 WO 2021165995 A1 WO2021165995 A1 WO 2021165995A1 IN 2021050164 W IN2021050164 W IN 2021050164W WO 2021165995 A1 WO2021165995 A1 WO 2021165995A1
Authority
WO
WIPO (PCT)
Prior art keywords
tenofovir alafenamide
malate
mono
crystalline
hemi
Prior art date
Application number
PCT/IN2021/050164
Other languages
English (en)
Inventor
Srinivas Laxminarayan Pathi
Ramanaiah CHENNURU
Ramesh DEVARAPALLI
Original Assignee
Cipla Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited filed Critical Cipla Limited
Priority to EP21714022.7A priority Critical patent/EP4085062A1/fr
Publication of WO2021165995A1 publication Critical patent/WO2021165995A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to novel salts and/or co-crystals of tenofovir alafenamide, process for preparation and the pharmaceutical formulations and therapeutic uses thereof.
  • the invention further provides novel crystalline forms of these novel salts.
  • Tenofovir alafenamide is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
  • the Tenofovir alafenamide fumarate (TAF) active ingredient in Vemlidy is present as tenofovir alafenamide hemifumarate.
  • TAF Tenofovir alafenamide fumarate
  • Solids can exist in different crystal forms, such as crystalline, amorphous, or glass and also in solvated or hydrated states (Haleblian et al., 1969,1975; Kuhnert- Brandstaetter, 1973; Sohn 2004).
  • Polymorphism is the ability of any element or compound to crystallize as more than one distinct crystal species.
  • the application WO2015040640 provides an improved process for the preparation of Tenofovir alafenamide or pharmaceutically acceptable salts namely ferulate, phosphate, succinate, citrate, tartrate, lactate, and methanesulfonate.
  • WO 2015/107451 Al discloses purification process of Tenofovir alafenamide suing chiral resolving agents such as (L)-(+)-tartaric acid, (D)-(-)-tartaric acid, (I S)-(+)- 10-camphor sulfonic acid, (lR)-(-)-10-camphor sulfonic acid, (15, 3R)-(-)- camphoric acid, (S)-(+)-mandelic acid, (R)-(-)-mandelic acid, benzoic acid, L- malic acid, succinic acid, oxalic acid, orthophosphoric acid, maleic acid, orotic acid,
  • WO2015176602 discloses Tenofovir alafenamide complex, preparation method and use thereof.
  • Preferred salts are selected from the group consisting of tenofovir alafenamide L-tartrate (1:2), tenofovir alafenamide D-tartrate (1:1), Tenofovir alafenamide tartrate (1:1), Tenofovir alafenamide L-malate (1:2), Tenofovir alafenamide citrate (1:1), tenofovir alafenamide succinate (1:1), tenofovir alafenamide oxalate (1:1), tenofovir alafenamide phosphate (1:1) and Tenofovir alafenamide sulfate (1:1).
  • WO2016192692A1 discloses solid forms of Tenofovir alafenamide with inorganic and organic acids and methods for preparing the same namely hydrochloric, hydrobromic, sulfuric, phosphoric, maleic, citric, succinic, tartaric, gallic, benzenesulfonic, salicylic and 4-aminobenzoic acids.
  • W02016205141/US 9,777,028 B2 discloses co-crystals, salts and crystalline forms of Tenofovir alafenamide and methods for preparation, use and isolation of such compounds.
  • the claimed salts are sesquifumarate, oxalate, malonate, L-malate saccharinate, mucate, maleate hydrochloride, ethanesulfonate, benzenesulfonate and crystal forms thereof.
  • the application WO 2018/115046 discloses crystalline polymorphic forms of Tenofovir alafenamide maleate, tenofovir alafenamide malonate, tenofovir alafenamide protocatechuate, and methods for preparing the same.
  • WO 2018/144390 A1 discloses crystalline polymorphic forms of Tenofovir alafenamide hemipamoate Form I and Form II, Tenofovir alafenamide sebacate Form I, Tenofovir alafenamide napsylate Form I, Tenofovir alafenamide orotate Form I, Form II and Form III, Tenofovir alafenamide vanillate, and Tenofovir alafenamide bis-xinafoate.
  • WO 2019/130354A1 discloses crystalline polymorphic forms of Tenofovir alafenamide monofumarate and Tenofovir alafenamide hemifumarate and methods for preparation, use and isolation of such compounds.
  • US 10,479,810 B2 discloses crystalline polymorphic forms of Tenofovir alafenamide fumarate such as Form II, Form A and Form B and methods for preparation, use and isolation of such compounds.
  • a drug and a salt thereof may exist in a plurality of crystalline form states, and different crystal forms of the same drug and its salt may have different dissolution and absorption in the body, thereby affecting dissolution and release of the preparation.
  • Tenofovir alafenamide or salts exhibits different polymorphic forms under differential conditions that include solvent, moisture, temperature, time and drying conditions and thus the bioavailability of the same also varies with polymorphic modification.
  • a change in crystal structure of compound by means of change in polymorphism affects physicochemical properties like dissolution and solubility, chemical and physical stability, flowability and hygroscopicity of a compound. Therefore, there remains a need in the art for solid forms of tenofovir alafenamide acid addition salts which are having greater stability, flowability, dissolution properties; thereby increasing the bioavailability of the drug.
  • An object of the present invention is to provide novel salts and/or co-crystals of Tenofovir alafenamide thereof.
  • Another object of the present invention is to provide a process for the preparation of novel salts and/or co-crystals of Tenofovir alafenamide thereof.
  • Yet another object of the invention is to provide pharmaceutical composition comprising a therapeutically effective amount of novel salts and/or co-crystals of Tenofovir alafenamide thereof.
  • Yet another object of the invention is to provide method of treatment of diseases or symptoms of HIV, wherein novel crystalline forms of salts and/or co-crystals of Tenofovir alafenamide thereof, are useful.
  • the present invention is directed to novel crystalline forms of salts and/or co-crystals of Tenofovir alafenamide.
  • the present invention provides acid salts selected from: Tenofovir alafenamide D-malate, and Tenofovir alafenamide adipate, or a solvate or hydrate thereof.
  • the present invention further provides methods of preparing a salt of the invention comprising steps of combining Tenofovir alafenamide with an acid selected from D-malic acid, or adipic acid, in a suitable solvent, and thereafter optionally isolating the acid addition salt so formed.
  • the present invention further provides one or more polymorphic forms or pseudo polymorphic forms of the salts of Tenofovir alafenamide. Accordingly, pseudo polymorphs provided include hydrates and/or solvates.
  • the present invention is directed to crystalline Tenofovir alafenamide mono D-malate Form Cl.
  • the present invention is directed to crystalline Tenofovir alafenamide hemi D-malate Form C2.
  • the present invention is directed to crystalline Tenofovir alafenamide mono adipate Form Cl.
  • the present invention is directed to the processes for the preparation of these novel crystalline salts and/or co-crystals of tenofovir alafenamide.
  • the invention further relates to a composition comprising one or more of the aforementioned novel crystalline salts and/or co-crystals of tenofovir alafenamide and processes for the preparation of the novel crystalline salts and/or co-crystals and the composition.
  • the invention relates to the use of the novel crystalline salts and/or co-crystals of Tenofovir alafenamide of the present invention for the preparation of a pharmaceutical composition and to a pharmaceutical composition comprising an effective amount of the novel crystalline salts and/or co-crystals of Tenofovir alafenamide of the present invention and and at least one pharmaceutically acceptable excipient.
  • the present invention is directed to methods of treating an HIV infection by administering a therapeutically effective amount of a salt and/or co-crystal of Tenofovir alafenamide provided herein.
  • the present invention is directed to the use of a salt and/or cocrystal of Tenofovir alafenamide provided herein in the manufacture of a medicament for treating an HIV infection.
  • Figure 1 depicts powder X-ray diffraction (PXRD) of Tenofovir alafenamide mono D-malate Form Cl.
  • Figure 2 depicts a DSC thermogram of Tenofovir Alafenamide mono D-malate Form Cl.
  • Figure 3 depicts a TGA thermogram of Tenofovir Alafenamide mono D-malate Form Cl.
  • Figure 4 depicts powder X-ray diffraction (PXRD) of Tenofovir alafenamide hemi D-malate Form C2
  • Figure 5 depicts a DSC thermogram of Tenofovir Alafenamide hemi D-malate Form C2.
  • Figure 6 depicts a TGA thermogram of Tenofovir Alafenamide hemi D-malate Form C2.
  • Figure 7 depicts powder X-ray diffraction (PXRD) of Tenofovir alafenamide mono adipate Form Cl.
  • Figure 8 depicts a DSC thermogram of Tenofovir Alafenamide mono adipate Form Cl.
  • Figure 9 depicts a TGA thermogram of Tenofovir Alafenamide mono adipate Form Cl.
  • Figure 10 depicts the pH - dependent solubility of the Tenofovir alafenamide hemi D-malate with Tenofovir alafenamide hemifumarate and Tenofovir alafenamide monofumarate in buffer solutions at pH 2.1
  • Figure 11 depicts the pH - dependent solubility of the Tenofovir alafenamide hemi D-malate with Tenofovir alafenamide hemifumarate and Tenofovir alafenamide monofumarate in buffer solutions at pH 4.5
  • Figure 12 depicts the pH - dependent solubility of the Tenofovir alafenamide hemi D-malate with Tenofovir alafenamide hemifumarate and Tenofovir alafenamide monofumarate in buffer solutions at pH 6.8 DETAILED DESCRIPTION OF THE INVENTION:
  • the present invention provides, inter alia, novel acid salts of the hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor Tenofovir alafenamide, selected from the D-malic acid salt, and adipic acid salt or a solvate or hydrate thereof. These salts are useful, for example, in the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
  • HBV hepatitis B virus
  • Salts of the present invention also include all isotopes of atoms occurring in the salts.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • the salts of the invention have numerous advantageous properties over the free base form and other salt forms.
  • these salts were highly crystalline which would facilitate the preparation of pharmaceutical formulations and improve general handling, manipulation, and storage of the active ingredient.
  • the salts of the invention also have superior aqueous solubility, rate of dissolution, chemical stability (with a longer shelf life), compatibility with excipients, and reproducibility compared with the free base form.
  • the salts of the invention are substantially isolated.
  • substantially isolated is meant that the salt is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, for example, a composition enriched in the salt of the invention.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the salt Salts of the invention can be prepared using known techniques.
  • a salt form is prepared by combining in solution the free base compound and an acid containing the anion of the salt form desired, and then isolating the solid salt product from the reaction solution (e.g., by crystallization, precipitation, evaporation, etc.).
  • Other salt-forming techniques can be employed.
  • solvated is understood to mean formation of a complex of variable stoichiometry comprising Tenofovir alafenamide salt and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include C1-C4 alcohol solvents, acetone, acetonitrile, methyl ethyl ketone (MEK), dimethylsulfoxide (DMSO), dichloromethane (MDC) and tetrahydrofuran (THF) and solvates other than water at levels of more than 1%.
  • the solvate can be isolated either as an amorphous form or in a crystalline form, preferably in crystalline form.
  • the solvate can be further isolated either in anhydrous form or hydrated form.
  • hydrate is understood as a substance that is formed by adding water molecules.
  • the skilled person will appreciate that the water molecules are absorbed, adsorbed or contained within a crystal lattice of the solid compounds, usually in defined stoichiometric ratio.
  • the notation for a hydrated compound may be nEbO, where n is the number of water molecules per formula unit of the compound. For example, in a hemihydrate, n is 0.5; in a monohydrate n is one; in a sesquihydrate, n is 1.5; in a dihydrate, n is 2; and so on.
  • one or more of the polymorphic forms provided may be a channel solvate.
  • channel solvate refers to a crystal lattice containing tunnels that can be occupied by solvent molecules (e.g., channel solvents), and other molecules and ions.
  • the term "substantially the same X-ray powder diffraction pattern" is understood to mean that those X-ray powder diffraction patterns having diffraction peaks with 2Q values within ⁇ 0.2° of the diffraction pattern referred to herein are within the scope of the referred to diffraction pattern.
  • DSC Differential Scanning Calorimetric
  • TGA Thermo Gravimetric Analysis
  • crystalline purity refers to a particular crystalline form of a compound in a sample which may contain amorphous form of the compound, one or more other crystalline forms of the compound other than the crystalline form of the compound of this invention, or a mixture thereof wherein the particular form of the compound is present in an amount of at least about 80%, preferably at least about 95%, most preferably at least about 99% crystalline.
  • crystal forms or amorphism of the present invention can be further identified by a variety of technical means, including, but not limited to infrared absorption spectroscopy (IR), melting point method, Nuclear magnetic resonance, Raman spectroscopy, dynamic vapor sorption (DYS), X-ray single crystal diffraction, dissolution calorimetry, scanning electron microscopy (SEM), quantitative analysis, solubility and dissolution rate or combination thereof.
  • IR infrared absorption spectroscopy
  • DYS dynamic vapor sorption
  • SEM scanning electron microscopy
  • novel acid salt of Tenofovir Alafenamide, Tenofovir Alafenamide D-malate may be in the form of a derivative thereof.
  • the derivative may be a pharmaceutically acceptable solvate, hydrate, tautomer, anhydrate, complex, polymorph, prodrug or combination thereof.
  • the D-malate salt may be isolated in pseudo polymorphic form as a solvate optionally in hydrated form, or as a non-hydrated solvate.
  • D-malic acid has two acid groups per molecule
  • compounds of these acids and Tenofovir alafenamide may be isolated as either mono- or di-acid addition salts and/or solvates thereof, having either one or two Tenofovir alafenamide molecules per acid molecule respectively.
  • the ratio of Tenofovir alafenamide to D-malic acid may range from about 1 to about 2 molecules of Tenofovir Alafenamide per 1 molecule of D-malic acid.
  • the ratio is 1 molecule of Tenofovir alafenamide per 1 molecule of D-malic acid.
  • the isolated salt is Tenofovir alafenamide mono D- malate.
  • the present invention relates to a process for preparing Tenofovir alafenamide mono D-malate which comprises reacting 1 mole Tenofovir alafenamide with 0.9 to 1.1 mole of D-malic acid in a suitable solvent.
  • the present invention relates to substantially pure Tenofovir alafenamide mono D-malate having a purity greater than 95%, preferably at least 99%, more preferably at least 99.5% area % by HPLC. In a further aspect, the present invention relates to substantially pure Tenofovir alafenamide mono D-malate having enantiomeric excess greater than 97%. Preferably greater than 98%, most preferably greater than 99%.
  • the mono D-malate salt according to the invention is characterised by good crystallinity and low amorphisation during grinding and compression. In addition, it is not hygroscopic and is readily soluble in physiologically acceptable solvents.
  • Form Cl Tenofovir alafenamide mono D-malate
  • the crystalline Tenofovir alafenamide mono D-malate Form Cl is relatively stable towards moisture and humidity, thereby representing a crystalline form of Tenofovir alafenamide, thus enhancing the efficacy of the parent molecule in lower doses.
  • the crystalline Tenofovir alafenamide mono D-malate Form Cl may be characterized by powder X-ray diffraction.
  • the crystalline Tenofovir alafenamide mono D-malate Form Cl may be characterized by having an XRPD diffractogram comprising peaks at 3.05, 9.06, 15.09 and 18.14 ⁇ 0.2°20.
  • the XRPD diffractogram may comprise further peaks at 14.22, 20.90, 24.28 and 28.72 ⁇ 0.2°20.
  • the XRPD diffractogram may be as depicted in Figure 1.
  • the crystalline Tenofovir alafenamide mono D-malate Form Cl may be characterized by having a DSC thermogram as shown in Figure 2.
  • the DSC plot for the sample shows an endotherm peak melting with an onset at 95.16°C, a peak maximum at 102.74 ⁇ 5°C, and an enthalpy change of 79.969 j/g.
  • the crystalline Tenofovir alafenamide mono D-malate Form Cl may be characterized by having a TGA thermogram substantially as depicted in Figure 3.
  • TGA data indicated a weight loss of 0.045% at temperatures up to 140°C.
  • the TGA analysis indicates the crystalline Tenofovir alafenamide mono D-malate Form Cl is the anhydrous form.
  • the Tenofovir alafenamide mono D-malate Form Cl has a crystalline purity of at least 80%, more preferably at least 90%, more preferably at least 95%, most preferably at least 99% by weight.
  • the ratio is 2 molecules of Tenofovir Alafenamide per 1 molecule of D-malic acid.
  • the isolated salt is Tenofovir alafenamide hemi D- malate.
  • the present invention relates to a process for preparing Tenofovir alafenamide hemi D-malate which comprises reacting 1 mole of Tenofovir alafenamide with 0.4 to 0.6 moles of D-malic acid in a suitable solvent.
  • the present invention relates to substantially pure Tenofovir alafenamide hemi D-malate having a purity greater than 95%, preferably at least 99%, more preferably at least 99.5% area % by HPLC.
  • the present invention relates to substantially pure Tenofovir alafenamide hemi D-malate having enantiomeric excess greater than 97%. Preferably greater than 98%, most preferably greater than 99%.
  • the hemi D-malate salt according to the invention is characterised by good crystallinity and low amorphisation during grinding and compression. In addition, it is not hygroscopic and is readily soluble in physiologically acceptable solvents.
  • Form C2 Tenofovir alafenamide hemi D-malate
  • the crystalline Tenofovir alafenamide hemi D-malate Form C2 is relatively stable towards moisture and humidity, thereby representing a crystalline form of Tenofovir alafenamide, thus enhancing the efficacy of the parent molecule in lower doses.
  • the crystalline Tenofovir alafenamide hemi D-malate Form C2 may be characterized by powder X-ray diffraction.
  • the crystalline Tenofovir alafenamide hemi D-malate Form C2 may be characterized by having an XRPD diffractogram comprising peaks at 3.93, 7.82, 15.19, 9.59 and 22.90 ⁇ 0.2°2Q.
  • the XRPD diffractogram may comprise further peaks at 12.35, 15.67, 17.10, 18.08, 19.24 and 24.83 ⁇ 0.2°20.
  • the XRPD diffractogram may be as depicted in Figure 4.
  • the crystalline Tenofovir alafenamide hemi D-malate Form C2 may be characterized by having a DSC thermogram as shown in Figure 5.
  • the DSC plot for the sample shows an endotherm peak melting with an onset at 114.14°C, a peak maximum at 121.95 ⁇ 5°C °C, and an enthalpy change of 83.179 j/g.
  • the crystalline Tenofovir alafenamide hemi D-malate Form C2 may be characterized by having a TGA thermogram substantially as depicted in Figure 6.
  • TGA data indicated a weight loss of 0.045% at temperatures up to 140°C.
  • the TGA analysis indicates the crystalline Tenofovir alafenamide hemi D-malate Form C2 is the anhydrous form.
  • the Tenofovir alafenamide hemi D-malate Form C2 has a crystalline purity of at least 80%, more preferably at least 90%, more preferably at least 95%, most preferably at least 99% by weight.
  • novel acid salt of Tenofovir Alafenamide, Tenofovir Alafenamide adipate may be in the form of a derivative thereof.
  • the derivative may be a pharmaceutically acceptable solvate, hydrate, tautomer, anhydrate, complex, polymorph, prodrug or combination thereof.
  • the adipate salt may be isolated in pseudo polymorphic form as a solvate optionally in hydrated form, or as a non-hydrated solvate.
  • one or more of the polymorphic forms provided may be a channel solvate.
  • channel solvate refers to a crystal lattice containing tunnels that can be occupied by solvent molecules (e.g., channel solvents), and other molecules and ions.
  • adipic acid has two acid groups per molecule
  • compounds of these acids and Tenofovir alafenamide may be isolated as either mono- or di-acid addition salts and/or solvates thereof having either one or two Tenofovir alafenamide molecules per acid molecule respectively.
  • the ratio of Tenofovir alafenamide to adipic acid may range from about 1 to about 2 molecules of Tenofovir alafenamide per 1 molecule of adipic acid.
  • the ratio is 1 molecule of Tenofovir alafenamide per 1 molecule of adipic acid.
  • the isolated salt is Tenofovir alafenamide mono adipate.
  • the present invention relates to a process for preparing Tenofovir alafenamide mono adipate which comprises reacting 1 mole of Tenofovir alafenamide with 0.9 to 1.1 moles of adipic acid in a suitable solvent.
  • the ratio is 2 molecules of Tenofovir alafenamide per 1 molecule of adipic acid.
  • the isolated salt is Tenofovir alafenamide hemi adipate.
  • the present invention relates to a process for preparing Tenofovir alafenamide hemi adipate which comprises reacting 2 moles of Tenofovir alafenamide with 0.9 to 1.1 moles of adipic acid in a suitable solvent.
  • the present invention relates to substantially pure Tenofovir alafenamide mono adipate having a purity greater than 95%, preferably at least 99%, more preferably at least 99.5% area % by HPLC.
  • the present invention relates to substantially pure Tenofovir alafenamide mono adipate having enantiomeric excess greater than 97%. Preferably greater than 98%, most preferably greater than 99%.
  • the mono adipate salt according to the invention is characterised by good crystallinity and low amorphisation during grinding and compression. In addition, it is not hygroscopic and is readily soluble in physiologically acceptable solvents.
  • the inventors have discovered a surprisingly advantageous crystalline polymorphic form of Tenofovir alafenamide mono adipate which hereinafter referred to as Form Cl. This form is described in more detail herein.
  • the crystalline Tenofovir alafenamide mono adipate Form Cl is relatively stable towards moisture and humidity, thereby representing a crystalline form of Tenofovir alafenamide, thus enhancing the efficacy of the parent molecule in lower doses.
  • the crystalline Tenofovir alafenamide mono adipate Form Cl may be characterized by powder X-ray diffraction.
  • the crystalline Tenofovir alafenamide mono adipate Form Cl may be characterized by having an XRPD diffractogram comprising peaks at 3.91, 6.25, 6.61, 15.74, 18.17 and 21.94 ⁇ 0.2°2Q.
  • the XRPD diffractogram may comprise further peaks at 8.05, 11.03, 12.09, 19.77 and 23.99 ⁇ 0.2°20.
  • the XRPD diffractogram may be as depicted in Figure 7.
  • the crystalline Tenofovir alafenamide mono adipate Form Cl may be characterized by having a DSC thermogram as shown in Figure 8.
  • the DSC plot for the sample shows an endotherm peak melting with an onset at 107.30°C, a peak maximum at 110.72 ⁇ 5°C, and an enthalpy change of 84.289 j/g.
  • the crystalline Tenofovir alafenamide mono adipate Form Cl may be characterized by having a TGA thermogram substantially as depicted in Figure 9.
  • TGA data indicated a weight loss of 0.069% at temperatures up to 140°C.
  • the TGA analysis indicates the crystalline Tenofovir alafenamide mono adipate Form Cl is the anhydrous form.
  • the Tenofovir alafenamide mono adipate Form Cl has a crystalline purity of at least 80%, more preferably at least 90%, more preferably at least 95%, most preferably at least 99% by weight.
  • the present invention provides a process for the preparation of novel salts of tenofovir alafenamide comprises steps of: a) providing a solution of tenofovir alafenamide in a suitable solvent, b) treating the solution with D-malic acid, or adipic acid, c) optionally treating with an antisolvent, d) optionally cooling the solution and optionally stirring, e) isolating tenofovir alafenamide salt, and f) drying
  • the above method further comprises: (bl) seeding the solution from step (b) with appropriate seed at room temperature and allowing the solution to stir until a slurry forms.
  • Providing a solution in step a) includes: i) direct use of a reaction mixture containing tenofovir alafenamide that is obtained in the course of its synthesis; or ii) dissolving tenofovir alafenamide in a suitable solvent optionally by heating.
  • the Tenofovir alafenamide may be obtained by the processes known in the art.
  • the tenofovir alafenamide used in preparing the salts and polymorphs may be obtained by methods described in the prior art which are herein incorporated by reference in their entirety.
  • the tenofovir alafenamide used as a starting material can be in any form, e.g. it can be in a reaction solution, suspension, crude or in amorphous, anhydrous, hydrated or solvated form.
  • Tenofovir alafenamide is dissolved in a suitable solvent to facilitate formation of the acid salt.
  • suitable solvents include, but are not limited to, alcohols such as methanol, ethanol, isopropanol, n-propanol, isobutanol, isoamyl alcohol, n-butanol, 1,2-dimethoxy ethanol, 2-m ethoxy ethanol, 2-ethoxy ethanol and ethylene glycol, and like; halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, carbon tetrachloride and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; esters such as methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, n-butyl acetate, t- butyl acetate and the
  • step b) the solution containing Tenofovir alafenamide is treated with D-malic acid, or adipic acid.
  • the acid may be in the form of a solution or solid.
  • the reaction may be carried out at elevated temperature to facilitate the reaction.
  • Suitable antisolvents used in the step c), include, but are not limited to, ethers such as diethyl ether, dimethyl ether, di-isopropyl ether, 1 ,4-dioxane tetrahydrofuran, isopropyl ether, diisopropyl ether (DIPE), methyl t-butyl ether (MTBE), and the like; hydrocarbons such as heptane, hexane, toluene, xylene and the like; and any mixtures of two or more thereof.
  • ethers such as diethyl ether, dimethyl ether, di-isopropyl ether, 1 ,4-dioxane tetrahydrofuran, isopropyl ether, diisopropyl ether (DIPE), methyl t-butyl ether (MTBE), and the like
  • hydrocarbons such as heptane, hexane,
  • step d) prior to the isolation the reaction material obtained in step c) of the process, is optionally cooled to a temperature range of -5°C to 30°C and stirred for about 10 minutes to about 10 hours, preferably for about 20 minutes to about 8 hours, more preferably for about 30 minutes hours to about 6 hours.
  • the resulting acid addition salt may be isolated as a solid by any one of the general techniques known in the art, including but not limited to, cooling, chilling, completely or partially removing solvents, and/or filtering.
  • Suitable techniques which can be used for the removal of solvent include but not limited to evaporation, flash evaporation, simple evaporation, rotational drying, spray drying, agitated thin-film drying, agitated nutsche filter drying, pressure nutsche filter drying, freeze-drying or any other suitable technique known in the art.
  • the solvent may be removed, optionally under reduced pressures, at temperatures less than about 100°C, less than about 75°C, less than about 60°C, less than about 50°C, or any other suitable temperatures.
  • step f) the solid isolated from step e), may be optionally further dried to afford novel salt forms of tenofovir alafenamide.
  • Drying can be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like.
  • the drying can be carried out at temperatures of less than about 70°C, less than about 60°C, less than about 50°C, less than about 40°C, less than about 30°C, or any other suitable temperatures; at atmospheric pressure or under a reduced pressure; as long as the product is not degraded in its quality.
  • Suitable time for drying can vary from few minutes to several hours for example from about 30 minutes to about 24 hours or more.
  • acid addition salts of Tenofovir alafenamide may be prepared in accordance with the present invention by a salt interconversion method. This process involves reacting an acid salt of Tenofovir alafenamide with a suitable base to form the free base of Tenofovir alafenamide and thereafter converting the free base so formed into an acid salt form (by addition of an acid from the present invention).
  • the obtained acid addition salts of Tenofovir alafenamide may be further purified.
  • Tenofovir alafenamide mono D-malate, Tenofovir alafenamide hemi D-malate and Tenofovir alafenamide mono adipate having a purity of at least 95%, preferably at least 99%, more preferably at least 99.5% area % by HPLC.
  • Crystalline forms of the present invention may be prepared by dissolving, crystallizing, stirring, evaporating the solvent or seeding with crystal. The crystals may be isolated form the reaction mixture by any of the general techniques known in the art.
  • the acid salts and polymorphic forms described herein may potentially exhibit improved properties.
  • the acid salts and polymorphic forms described herein may potentially exhibit improved long term physical and chemical stability. Such improved stability could have a potentially beneficial impact on the manufacture of the Tenofovir alafenamide, such as for example offering the ability to store process intermediate for extended periods of time. Improved stability could also potentially benefit a composition or pharmaceutical composition of the Tenofovir alafenamide.
  • the salts and polymorphic forms described herein may also potentially result in improved yield of the Tenofovir alafenamide, or potentially result in an improvement of the quality of the Tenofovir alafenamide.
  • the salts and polymorphic described herein may also exhibit improved pharmacokinetic properties and/or potentially improved bioavailability.
  • the acid salts and polymorphic forms of the present invention may be administered by any route appropriate to the condition to be treated. Suitable administration routes include, but are not limited to, oral, rectal, nasal, pulmonary, topical, vaginal and parenteral.
  • the acid salts and polymorphic forms of the present invention may be formulated as solid compositions together with a pharmaceutically acceptable carrier, glidant, diluent, or excipient, for oral administration in the form of capsules, tablets, pills, powders or granules.
  • compositions of the present invention comprise a Tenofovir alafenamide or a pharmaceutically acceptable acid addition salt thereof of the type disclosed herein, together with one or more pharmaceutically acceptable excipients, and optionally one or more further active pharmaceutical ingredients.
  • the pharmaceutical composition of the present invention is formulated to provide immediate release of the active pharmaceutical ingredient(s) present therein.
  • the pharmaceutical composition of the present invention is formulated to provide controlled release of the active pharmaceutical ingredient(s) present therein. Controlled release comprises delayed, sustained and pulsed release of the active pharmaceutical ingredient(s).
  • Suitable pharmaceutical excipients are known in the art and include, but are not limited to, carriers, diluents and/or vehicles.
  • the excipients (s) must be "acceptable” in the sense of being compatible with the other ingredients of the pharmaceutical composition and not harmful to the patient.
  • the excipient(s) may be selected to provide a desired release profile of the active pharmaceutical ingredient(s) present.
  • compositions of the present invention comprise a therapeutically effective amount of Tenofovir alafenamide or a pharmaceutically acceptable acid addition salt thereof.
  • Suitable dosages include, but are not limited to, 150 mg, and 200mg.
  • Example 1 Process to prepare Tenofovir alafenamide mono D-malate
  • NMR spectrum showed a 1:1 stoichiometry ratio of Tenofovir alafenamide to D- malic acid.
  • NMR spectrum showed a 1:1 stoichiometry ratio of Tenofovir alafenamide to D- malic acid.
  • NMR spectrum showed a 2:1 stoichiometry ratio of Tenofovir alafenamide to D- malic acid.
  • Example 4 Process to prepare Tenofovir alafenamide hemi D-malate
  • NMR spectrum showed a 2:1 stoichiometry ratio of Tenofovir alafenamide to D- malic acid.
  • Tenofovir alafenamide hemi D-malate may exhibit long-term physical and chemical stability.
  • Table 1 shows laboratory data collected on Tenofovir alafenamide hemi D-malate, all prepared according to the processes disclosed in the present disclosure. The data demonstrate that Tenofovir alafenamide hemi D-malate show no significant degradation or change in PXRD pattern (e.g., is stable at 1, 2 and 3 months storage) when stored for 3 months at 40 ⁇ 2°C/75 ⁇ 5% relative humidity (RH).
  • RH relative humidity
  • Tenofovir alafenamide hemi D-malate displayed better long term storage stability with significantly less than 1 % degradation over three months under those conditions.
  • Table 1 shows no significant degradation or change in the XRPD pattern when stored at 2 to 8C or 25 ⁇ 2°C/60 ⁇ 5%RH or 40 ⁇ 2°C/75 ⁇ 5%RH, indicates that Tenofovir alafenamide hemi D-malate has improved thermal stability.
  • Example 6 Determination of the solubility of Tenofovir alafenamide hemi D- malate in buffered solutions (Solubility as a Function of pH )
  • the aqueous solubility of Tenofovir alafenamide hemi D-malate was compared with Tenofovir alafenamide hemifumarate and Tenofovir alafenamide monofumarate.
  • the solubility of salts of the invention was determined at pH 2.1 (Gastric Buffer), pH 4.5 (Acetate Buffer) and pH 6.8 (Intestinal Buffer), by suspending 1-5 mg of each salt in 10 mL of corresponding aqueous solution. The samples were allowed to equilibrate at ambient temperature for at least 24 hours for pH 2.1, 4.5 and 6.8 Buffers. The supernatant was filtered and used for the solubility determination by UV-VIS spectroscopy. The solid residue was analyzed by XRPD.
  • NMR spectrum showed a 1 : 1 stoichiometry ratio of Tenofovir alafenamide to adipic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux sels et/ou co-cristaux de ténofovir alafénamide avec un acide choisi parmi l'acide D-malique et l'acide adipique. Un autre aspect de la présente invention concerne de nouvelles formes cristallines des nouveaux sels et/ou co-cristaux de ténofovir alafénamide, un procédé de préparation, les formulations pharmaceutiques et leurs utilisations thérapeutiques pour le traitement de maladies ou de symptômes de l'infection par le VIH et de l'hépatite B virale.
PCT/IN2021/050164 2020-02-20 2021-02-20 Nouveaux sels et/ou co-cristaux de ténofovir alafénamide WO2021165995A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21714022.7A EP4085062A1 (fr) 2020-02-20 2021-02-20 Nouveaux sels et/ou co-cristaux de ténofovir alafénamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021007275 2020-02-20
IN202021007275 2020-02-20

Publications (1)

Publication Number Publication Date
WO2021165995A1 true WO2021165995A1 (fr) 2021-08-26

Family

ID=75173407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050164 WO2021165995A1 (fr) 2020-02-20 2021-02-20 Nouveaux sels et/ou co-cristaux de ténofovir alafénamide

Country Status (2)

Country Link
EP (1) EP4085062A1 (fr)
WO (1) WO2021165995A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008241A2 (fr) 2000-07-21 2002-01-31 Gilead Sciences, Inc. Promedicaments a base d"analogues nucleotidiques de phosphonate et leurs methodes de selection et d"elaboration
WO2013025788A1 (fr) * 2011-08-16 2013-02-21 Gilead Sciences, Inc. Hémifumarate de ténofovir alafénamide
WO2015040640A2 (fr) 2013-09-20 2015-03-26 Laurus Labs Private Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
WO2015107451A2 (fr) 2014-01-14 2015-07-23 Mylan Laboratories Ltd. Purification de ténofovir alafénamide et de ses intermédiaires
WO2015176602A1 (fr) 2014-05-20 2015-11-26 四川海思科制药有限公司 Complexe de ténofovir alafénamide, son procédé de préparation et utilisation
WO2016192692A1 (fr) 2015-06-05 2016-12-08 Zentiva K.S. Formes solides d'alafénamide de ténofovir
WO2016205141A1 (fr) 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-cristaux, sels et formes solides de ténofovir alafénamide
WO2018115046A1 (fr) 2016-12-23 2018-06-28 Sandoz Ag Formes solides cristallines de ténofovir alafénamide
WO2018144390A1 (fr) 2017-01-31 2018-08-09 Gilead Sciences, Inc. Formes cristallines de ténofovir alafénamide
WO2019130354A1 (fr) 2017-12-30 2019-07-04 Cipla Limited Formes polymorphes de (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)éthyl]amino]phénoxy phosphinyl]méthoxy]propyl]adénine et leurs sels pharmaceutiquement acceptables
US10479810B2 (en) 2016-06-05 2019-11-19 Shanghai Begreat Pharmatech Crystal form of tenofovir alafenamide salt, preparation method and use thereof

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008241A2 (fr) 2000-07-21 2002-01-31 Gilead Sciences, Inc. Promedicaments a base d"analogues nucleotidiques de phosphonate et leurs methodes de selection et d"elaboration
WO2013025788A1 (fr) * 2011-08-16 2013-02-21 Gilead Sciences, Inc. Hémifumarate de ténofovir alafénamide
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
WO2015040640A2 (fr) 2013-09-20 2015-03-26 Laurus Labs Private Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
WO2015107451A2 (fr) 2014-01-14 2015-07-23 Mylan Laboratories Ltd. Purification de ténofovir alafénamide et de ses intermédiaires
WO2015176602A1 (fr) 2014-05-20 2015-11-26 四川海思科制药有限公司 Complexe de ténofovir alafénamide, son procédé de préparation et utilisation
WO2016192692A1 (fr) 2015-06-05 2016-12-08 Zentiva K.S. Formes solides d'alafénamide de ténofovir
WO2016205141A1 (fr) 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-cristaux, sels et formes solides de ténofovir alafénamide
US9777028B2 (en) 2015-06-17 2017-10-03 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
US10479810B2 (en) 2016-06-05 2019-11-19 Shanghai Begreat Pharmatech Crystal form of tenofovir alafenamide salt, preparation method and use thereof
WO2018115046A1 (fr) 2016-12-23 2018-06-28 Sandoz Ag Formes solides cristallines de ténofovir alafénamide
WO2018144390A1 (fr) 2017-01-31 2018-08-09 Gilead Sciences, Inc. Formes cristallines de ténofovir alafénamide
WO2019130354A1 (fr) 2017-12-30 2019-07-04 Cipla Limited Formes polymorphes de (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)éthyl]amino]phénoxy phosphinyl]méthoxy]propyl]adénine et leurs sels pharmaceutiquement acceptables

Also Published As

Publication number Publication date
EP4085062A1 (fr) 2022-11-09

Similar Documents

Publication Publication Date Title
WO2011158248A2 (fr) Procédé pour la préparation de posaconazole et forme polymorphique cristalline v de posaconazole
US20180237438A1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
US20220144851A1 (en) Novel polymorphs of integrase inhibitor
IL226616A (en) Polymorph of chemically pure nor – udca, methods for its preparation and uses for the treatment of liver disease
AU2018234306B2 (en) Salts of antiviral phosphonate analogues and process for preparation thereof
WO2007031865A2 (fr) Forme polymorphique d'hydrochlorure de lercanidipine et son procede de preparation
US11230559B2 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate
US9169257B2 (en) Crystal forms of adefovir dipivoxil and processes for preparing the same
WO2013132314A1 (fr) Phosphate de type ténofovir, procédés de préparation et composition pharmaceutique de celui-ci
WO2021165995A1 (fr) Nouveaux sels et/ou co-cristaux de ténofovir alafénamide
US20220009929A1 (en) Polymorphic forms of ibrutinib
US20230075170A1 (en) Novel salts of nilotinib and polymorphic forms thereof
US20200407382A1 (en) Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
CN109843880B (zh) 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型
EP3710425A1 (fr) Formes à l'état solide d'elafibranor
EP2997031A1 (fr) Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique
US20230373998A1 (en) Solid state forms of lorecivivint
WO2002038545A2 (fr) Forme cristalline de solvate d'ethylate de zafirlukast, procede de preparation de cette derniere et compositions pharmaceutiques comprenant cette derniere
US20220119415A1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US20220119414A1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2022224269A1 (fr) Co-cristaux, sels et formes solides de niraparib
WO2020107335A1 (fr) Sels cristallins de corydalmine
CN117624241A (zh) 一种tlr激动剂或其盐的多晶型物制备
WO2024069574A1 (fr) Formes à l'état solide de denifanstat
WO2020086789A1 (fr) Nouveaux polymorphes cristallins de sodium de rigosertib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21714022

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021714022

Country of ref document: EP

Effective date: 20220802